Legato Capital Management LLC Cuts Position in Stereotaxis, Inc. (NYSEAMERICAN:STXS)

Legato Capital Management LLC trimmed its position in Stereotaxis, Inc. (NYSEAMERICAN:STXS) by 23.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 360,291 shares of the company’s stock after selling 111,859 shares during the quarter. Legato Capital Management LLC owned 0.43% of Stereotaxis worth $821,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Stereotaxis in the third quarter valued at about $39,000. Jane Street Group LLC grew its stake in shares of Stereotaxis by 26.9% in the third quarter. Jane Street Group LLC now owns 29,773 shares of the company’s stock valued at $61,000 after buying an additional 6,313 shares in the last quarter. Wealth Effects LLC grew its stake in shares of Stereotaxis by 11.7% in the fourth quarter. Wealth Effects LLC now owns 86,060 shares of the company’s stock valued at $196,000 after buying an additional 9,000 shares in the last quarter. Barclays PLC grew its stake in shares of Stereotaxis by 449.9% in the third quarter. Barclays PLC now owns 101,953 shares of the company’s stock valued at $208,000 after buying an additional 83,412 shares in the last quarter. Finally, Traynor Capital Management Inc. acquired a new stake in shares of Stereotaxis in the fourth quarter valued at about $366,000. 45.35% of the stock is currently owned by hedge funds and other institutional investors.

Stereotaxis Stock Up 5.6 %

STXS stock opened at $2.27 on Friday. Stereotaxis, Inc. has a 1 year low of $1.66 and a 1 year high of $3.29. The stock has a market capitalization of $192.34 million, a PE ratio of -8.11 and a beta of 1.54.

Stereotaxis (NYSEAMERICAN:STXS) last posted its earnings results on Monday, November 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 162.54%. The company had revenue of $9.20 million during the quarter, compared to analyst estimates of $6.80 million. Equities analysts predict that Stereotaxis, Inc. will post -0.26 earnings per share for the current year.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.